Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 4
1970 2
1971 3
1972 2
1973 1
1975 1
1978 1
1979 3
1980 1
1981 1
1983 3
1984 3
1985 3
1986 6
1987 8
1988 8
1989 3
1990 5
1991 4
1992 6
1993 5
1994 5
1995 6
1996 6
1997 2
1998 3
1999 3
2000 4
2001 2
2002 4
2003 3
2004 4
2005 4
2006 4
2007 4
2009 5
2010 11
2011 10
2012 11
2013 11
2014 8
2015 16
2016 22
2017 15
2018 16
2019 19
2020 16
2021 17
2022 17
2023 9
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for minton n
Search for Minten N instead (2 results)
Pathogenicity and virulence of Clostridium botulinum.
Rawson AM, Dempster AW, Humphreys CM, Minton NP. Rawson AM, et al. Among authors: minton np. Virulence. 2023 Dec;14(1):2205251. doi: 10.1080/21505594.2023.2205251. Virulence. 2023. PMID: 37157163 Free PMC article. Review.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: minton n. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Among authors: minton n. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Among authors: minton n. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
ClosTron-targeted mutagenesis.
Heap JT, Cartman ST, Kuehne SA, Cooksley C, Minton NP. Heap JT, et al. Among authors: minton np. Methods Mol Biol. 2010;646:165-82. doi: 10.1007/978-1-60327-365-7_11. Methods Mol Biol. 2010. PMID: 20597009
Syngas Biorefinery and Syngas Utilization.
De Tissera S, Köpke M, Simpson SD, Humphreys C, Minton NP, Dürre P. De Tissera S, et al. Among authors: minton np. Adv Biochem Eng Biotechnol. 2019;166:247-280. doi: 10.1007/10_2017_5. Adv Biochem Eng Biotechnol. 2019. PMID: 28631029 Review.
Clostridia in cancer therapy.
Minton NP. Minton NP. Nat Rev Microbiol. 2003 Dec;1(3):237-42. doi: 10.1038/nrmicro777. Nat Rev Microbiol. 2003. PMID: 15035028 Review.
311 results